<DOC>
	<DOCNO>NCT00506701</DOCNO>
	<brief_summary>Tadalafil may lower pulmonary artery pressure patient Chronic Obstructive Lung Disease secondary pulmonary hypertension thereby improve patient quality life .</brief_summary>
	<brief_title>Effect Tadalafil Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension</brief_title>
	<detailed_description>Twenty outpatient Chronic Obstructive Lung Disease ( COPD ) secondary pulmonary hypertension treat cross-over design Tadalafil placebo 4 week . Primary effect parameter 6 min . walk test .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Clinical diagnosis Chronic obstructive lung disease Exclusion Criteria Patients asthma</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>